ALNA.Q Stock Overview
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Allena Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0009 |
| 52 Week High | US$0.44 |
| 52 Week Low | US$0.000001 |
| Beta | 1.51 |
| 1 Month Change | 800.00% |
| 3 Month Change | 12.50% |
| 1 Year Change | -99.24% |
| 3 Year Change | -99.97% |
| 5 Year Change | -99.99% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment
Jul 19Allena Pharma reschedules special meeting to approve reverse stock split, shares fall
Jul 05Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days
Jan 08Should You Review Recent Insider Transactions At Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)?
Dec 29
Allena Pharmaceuticals announces $10M bought deal
Dec 01Allena Pharma's ALLN-346 shows encouraging action in early-stage study
Nov 30Allena Pharmaceuticals (ALNA) Investor Presentation - Slideshow
Nov 11Allena Pharmaceuticals EPS misses by $0.01
Nov 09Shareholder Returns
| ALNA.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 350.0% | 1.6% | 1.3% |
| 1Y | -99.2% | -7.2% | 24.4% |
Return vs Industry: ALNA.Q underperformed the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: ALNA.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| ALNA.Q volatility | |
|---|---|
| ALNA.Q Average Weekly Movement | 349.4% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ALNA.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ALNA.Q's weekly volatility has increased from 187% to 349% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 12 | n/a | www.allenapharma.com |
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Allena Pharmaceuticals, Inc. Fundamentals Summary
| ALNA.Q fundamental statistics | |
|---|---|
| Market cap | US$109.87k |
| Earnings (TTM) | -US$43.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ALNA.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALNA.Q income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.30m |
| Earnings | -US$43.30m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 131.1% |
How did ALNA.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/30 20:27 |
| End of Day Share Price | 2023/05/30 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Allena Pharmaceuticals, Inc. is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Madhu Kumar | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |